Abstract:Abstract Background One of the major challenges in currently chemotherapeutic theme is lacking effective biomarkers for drug response and sensitivity. Our current study focus on two promising biomarkers, ERCC1 (excision repair cross-complementing group 1) and BRCA1 (breast cancer susceptibility gene 1). To investigate their potential role in serving as biomarkers for drug sensitivity in cancer patients with metastases, we statistically measure the mRNA expression level of ERCC1 and BRCA1 in tumor cells isolated from malignant effusions and correlate them with cisplatin and/or docetaxel chemosensitivity. Methods Real-time quantitative PCR is used to analysis related genes expression in forty-six malignant effusions prospectively collected from non-small cell lung cancer (NSCLC), gastric and gynecology cancer patients. Viable tumor cells obtained from malignant effusions are tested for their sensitivity to cisplatin and docetaxel using ATP-TCA assay. Results ERCC1 expression level is negatively correlated with the sensitivity to cisplatin in NSCLC patients (P = 0.001). In NSCLC and gastric group, BRCA1 expression level is negatively correlated with the sensitivity to cisplatin (NSCLC: P = 0.014; gastric: P = 0.002) while positively correlated with sensitivity to docetaxel (NSCLC: P = 0.008; gastric: P = 0.032). A significant interaction is found between ERCC1 and BRCA1 mRNA expressions on sensitivity to cisplatin (P = 0.010, n = 45). Conclusion Our results demonstrate that ERCC1 and BRCA1 mRNA expression levels are correlated with in vitro chemosensitivity to cisplatin and/or docetaxel in malignant effusions of NSCLC and gastric cancer patients. And combination of ERCC1 and BRCA1 may have a better role on predicting the sensitivity to cisplatin than the single one is considered.

Excision repair cross complementing-1 gene expression in small cell lung cancer and chemo-sensitivity to cisplatin/etoposide regimen

Meta-analysis of excision repair cross-complementation group 1 (ERCC1) association with response to platinum- based chemotherapy in ovarian cancer.

Expression of ERCC-1 in NSCLC tissue and its value for appraising chemotherapy

Expression of excision repair cross-complementation group 1 in non-small-cell lung cancer and its contribution to Cisplatin-based adjuvant chemotherapy

A Meta-Analysis Identifies ERCC1 Gene Polymorphism As a Predictor of Better Patient Response to Treatment with Radiochemotherapy

Study on the relationship between expression levels of ERCC1 mRNA and sensitivity of tumor cells isolated from malignant effusions to cisplatin in vitro

High Expression of ERCC1 is a Poor Prognostic Factor in Chinese Patients with Non-Small Cell Lung Cancer Receiving Cisplatin-Based Therapy

Positive Expression of ERCC1 Predicts a Poorer Platinum-Based Treatment Outcome in Chinese Patients with Advanced Non-Small-cell Lung Cancer

Expression of ERCC1 and BRCA1 Predict the Clinical Outcome of Non-Small Cell Lung Cancer in Patients Receiving Platinum-Based Chemotherapy.

Prognostic Significance of ERCC1 Mrna Expression in Patients with Non-Small Cell Lung Cancer Receiving Platinum-Based Chemotherapy

Protein Expression Levels Of Excision Repair Cross-Complementation Group 1 And Xeroderma Pigmentosum D Correlate With Response To Platinum-Based Chemotherapy In The Patients With Advanced Epithelial Ovarian Cancer

First-line Gemcitabine Plus Cisplatin in Nonsmall Cell Lung Cancer Patients.

Relationship Between Expression of ERCC1 and Effect of Platinum-based Chemotherapy in Patients with Advanced NSCLC

ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel

Relation between the expression of ERCC1 and the clinicopathology characteristics in advanced non-small cell lung cancer

Meta-Analysis of Predictive Value of ERCC1 Protein Expression in Non-Small Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy

ERCC1 and BRCA1 Expressions in the Tissues of Colorectal Cancer and Its Relationship with Clinical Significance of Platinum-Based Chemotherapy

Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response

Expression Of Ercc1 And Class Iii Beta-Tubulin In Resected Non-Small Cell Lung Cancer And Its Correlation With Platinum-Based Adjuvant Chemotherapy

Increased ERCC1 Protein Expression is Associated with Suboptimal Debulking in Advanced Epithelial Ovarian Cancer.

ERCC1 expression status predicts the response and survival of patients with metastatic or recurrent cervical cancer treated via platinum-based chemotherapy